Doug is Managing Partner at Health2047 Capital Partners LLC 2018-present. He served as Health2047’s Chief Executive from its founding in 2015 until 2018. Doug has spent more than two decades in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. Doug is a physician and medical scientist. Beginning in 1983 he has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur. In addition to a number of private companies, he led three public biopharmaceutical companies as CEO.

Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc, Board Chair at Arrowhead Pharmaceuticals (NASDAQ:ARWR), Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc, BrYet Health Ltd, Visirna Therapeutics, and Vivaldi Biosciences Inc. He serves in advisory roles on the University of Chicago Pritzker School of Medicine, and Biological Sciences Division Council (former Chair), Johns Hopkins Bloomberg School of Public Health, Health Advisory Board.

Doug received MD and PhD degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania and was a Clinical and Research Fellow in internal medicine and infectious diseases at Massachusetts General Hospital and Harvard Medical School.